Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's ... a strong Q1 earnings report from Lilly and immediately raised concerns from ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

If a person’s doctor prescribes Zepbound for OSA and the drug is in their Part D plan’s formulary, they should receive Medicare coverage for it. Medicare does not currently cover Zepbound and ...

Zepbound's prescription ... struggles with supply issues in 2024. CVS's pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... detention center Transgender issues are a strength for Trump ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...